Start A Project

Overview

Long-Read Pharmacogenomics combines Twist Bioscience hybridization capture with Oxford Nanopore sequencing to profile 49 pharmacogenes and mitochondrial DNA targets. This approach resolves phased variants, repeat lengths, and CYP2D6 structural complexity in a single assay.
  • Phased diplotypes from read-based phasing
  • CYP2D6 copy number and hybrid allele resolution
  • Repeat sizing, including UGT1A1*28
  • Standardized PharmCAT and Chinook reporting
DNA icons
Full-Gene Haplotyping
Phasing across 39 full-length genes
Repeat sizing and rare variant detection
interesting process icon
Structural Variant Resolution
CYP2D6 copy number and hybrid alleles
Complex DPYD and CYP2C haplotypes
dotted bow tie icon
Clinical Development Applications
Pharmacokinetic and safety studies in trials. Retrospective and multi-population studies
Technology
Workflow
Performance
Data Outputs
Target Panel Design

Technology and Compatibility

Long-Read Pharmacogenomics combines Twist Bioscience hybridization capture and PCR amplification with ONT long-read sequencing, enabling resolution of complex pharmacogenomic variants and structural features.
  • Compatible with
  • High-molecular-weight human genomic DNA
  • Cultured human cells
  • Whole blood (fresh or frozen)
  • Component
    Technology
  • Target Enrichment Library
    Twist Bioscience hybridization capture and PCR amplification
  • Library Preparation
    Enriched DNA is prepared using a modified ligation-based method
  • Sequencing Platform
    Oxford Nanopore PromethION

Workflow

Long-Read Pharmacogenomics combines Twist Bioscience hybridization capture and PCR amplification with Oxford Nanopore long-read sequencing to resolve complex pharmacogenomic variants. Renew provides full-service support from gDNA extraction through library preparation, sequencing, bioinformatics analysis, and data delivery.
  • 1. gDNA Extraction
    High-molecular-weight DNA is extracted from input samples
  • 2. DNA Fragmentation
    DNA is sheared to >10 kb to preserve long-range context
  • 3. Target Enrichment
    PGx targets are enriched using Twist hybridization capture and PCR amplification
  • 4. Library Preparation
    Enriched DNA is prepared using a modified ligation-based method
  • 5. Long-Read Sequencing
    Libraries are sequenced on the Oxford Nanopore PromethION platform
  • 6. Bioinformatic Analysis
    Variants, diplotypes, and CYP2D6 structures are called using wf-pgx, PharmCAT, and Chinook

Sequencing Performance

Coverage and yield vary by genome size, input quality, multiplexing strategy, and study goals. Representative performance metrics are shown below.
  • Metric
    Reported Study Result
  • Panel Mean On-Target Coverage
    >100x
  • Mean Base Quality
    >Q25
  • Read Length (N50)
    >3 kb
  • Small-Variant F1 vs. GIAB
    >0.95
  • AUPRC vs. GIAB
    >0.92
  • Samples per Flow Cell
    48

Bioinformatics and Data Outputs

Renew provides standardized PGx bioinformatics outputs designed for efficient storage, transfer, and downstream analysis, including PharmCAT diplotype reporting and Chinook CYP2D6 structural analysis. Project files are delivered through the Client Portal, with AWS S3 or API-based transfer available as needed.
  • Data Outputs
  • QC Report
    Sequencing metrics and run statistics
  • BAM
    Aligned reads
  • VCF
    Phased small variants
  • PGx Report
    PharmCAT diplotypes and Chinook CYP2D6 structures
  • POD5
    Raw sequencing data (available for an additional fee)
  • Data Delivery Options
  • Client Web Portal
    Manual download | Mac, Linux, Windows
  • AWS S3 Transfer
    Automated process | AWS to AWS
  • Command Line Script
    Manual download | Mac, Linux

Target Panel Design

The Long-Read PGx panel targets 49 pharmacogenes and mitochondrial DNA, covering 39 full-length genes and key variants across 10 additional genes. Panel content can be customized to prioritize genes and variants for program-specific research needs.
  • Parameter
    Specification
  • Number of Targets
    49 PGx genes + variant hotspots
  • Coverage Design
    39 full-length genes, 10 hotspots with key PGx variants
  • Probe Platform
    Twist Bioscience
  • Nuclear Genes Targets (48)
    ABCB1, ABCG2, ADD1, ADRA2A, ANKK1, APOL1, BCHE, CACNA1S, CFTR, COMT, CTBP2, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP4F2, DPYD, DRD2, F2, F5, GBA, GRIK4, G6PD, HLA-A, HLA-B, HLA-DRB1, HLA-DQA1, HTR2C, IFNL3, MTHFR, NAGS, NAT2, NUDT15, OPRD1, OPRK1, OPRM1, POLG, RYR1, SLC6A4, SLCO1B1, TPMT, UGT1A1, UGT2B15, VKORC1, YEATS4
  • Mitochondrial Gene Target (1)
    MT-RNR1
  • Target Size
    10 kb

Service Inclusions

Each project is supported by dedicated project management and cross-functional expertise across assay development, bioinformatics, and regulatory strategy. Renew provides proactive communication, transparent project tracking, and technical support from study design through data delivery.

Questions & Answers

What is long-read pharmacogenomics, and how does it differ from short-read or array-based PGx testing?

Long-read pharmacogenomics uses long DNA sequencing reads to genotype pharmacogenes with variants phased directly from the reads. Short-read and SNP array tests often infer phase and can miss repeats, rare variants, and copy-number changes. Long reads measure these features directly, producing diplotypes and structural context from a single targeted assay.

Why is CYP2D6 difficult to genotype, and how does long-read sequencing help?

CYP2D6 can be deleted, duplicated, or fused with the neighboring CYP2D7 pseudogene to form hybrid alleles, structures that short reads often cannot distinguish. Long reads capture these structures in the same data used for small-variant calling. Chinook-based analysis then reports CYP2D6 star alleles with copy number and hybrid structure, such as *1/*4×2 or *36+*10.

Why does haplotype phasing matter for DPYD and UGT1A1?

Phasing shows whether two variants sit on the same copy of a gene or on different copies, which can change the assigned diplotype and predicted metabolizer phenotype. For DPYD, this matters when a sample carries more than one variant. For UGT1A1, long reads size the *28 promoter TA repeat directly, alongside nearby variants on the same haplotype.

Which pharmacogenes are included in the Long-Read PGx panel?

The panel covers 49 pharmacogenes plus mitochondrial DNA: 39 genes sequenced full-length and 10 targeted at key PGx variants. Genes include CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, DPYD, UGT1A1, TPMT, NUDT15, SLCO1B1, VKORC1, G6PD, HLA-A, and HLA-B. The complete gene list is available in the case study.

What sample types can I submit, including banked clinical trial samples?

Renew accepts human genomic DNA and whole blood collected in a standard EDTA tube. We also work with banked samples from completed or ongoing studies, and our team reviews archived DNA quality before sequencing. Questions about sample preparation or shipping can be directed to info@renewbt.com.

What is the turnaround time for a Long-Read PGx project?

Typical turnaround is 14-21 days from sample receipt to data delivery. Timelines depend on sample count, sample quality, and analysis scope, and are confirmed during project setup. Live project status is available through the customer portal.

Can Long-Read PGx be used in clinical trials?

Yes, for exploratory analyses. Long-Read PGx supports research use and fit-for-purpose studies, such as PGx covariates in safety, PK, and PK/PD analyses, in prospective and retrospective designs. For programs with an intended clinical use, Renew offers assay validation pathways through our CAP/CLIA-certified laboratory.

Can the PGx panel be customized for my program?

Yes. Genes can be added or prioritized based on your program's compounds and metabolic pathways. Renew's Targeted Panel Development team supports custom capture design and validation.

What deliverables will I receive, and are they compatible with our data systems?

Each project includes a QC report, aligned reads (BAM), phased variant calls (VCF), and a PGx report with PharmCAT diplotypes and Chinook CYP2D6 structures. Reporting formats can be adapted for sponsor and CRO data systems, with delivery through the customer portal or AWS S3.

Renew combines platform flexibility, nanopore expertise, and operational excellence to resolve areas
of the genome that standard approaches cannot.
Contact Us